ExSight Ventures — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Valitorvalitorbio.com inOct 2022

Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.

BiotechMedical DevicesBerkeley, US

Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)

BoardDrew Lanza(Director)in

Co-investorsAngel Physicians Fund Berkeley Catalyst First Spark Ventures, Llc Pandect Bioventures Taihill Venture

Vanavana.org 𝕏Nov 2022 · $11.9M

Vana is an open data infrastructure platform that enables individuals to control and manage the data they generate, with the ability to choose how it is used by AI systems.

AI & Machine LearningCrypto & Web3Data & Infrastructure

Art Abal(Founder)Anna Kazlauskas(Founder)

Co-investorsAbstract Ventures AlphaLab Capital BoxGroup Caladan Earl Grey Capital Flori Ventures +15 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.